Previous studies have demonstrated the associations of PIK3CA mutations44 and CASP845 mutations with increased immune infiltration in cancer, consistent with the highly enriched anti-tumor immune signatures in ImE vs. ImD and StE. This evidence concerns the gene PIK3CA and cancer.